Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

A double-blind randomized trial in South Africa documented poor efficacy of two doses of the ChAdOx1 nCoV-19 vaccine against the B.1.351 variant of SARS-CoV-2 that emerged in South Africa. Infections occurred in 3.2% of placebo recipients and in 2.5% of vaccine recipients. Thirty-nine of the 42 viru...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-05, Vol.384 (20), p.1885-1898
Hauptverfasser:	Madhi, Shabir A, Baillie, Vicky, Cutland, Clare L, Voysey, Merryn, Koen, Anthonet L, Fairlie, Lee, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim E, Briner, Carmen, Kwatra, Gaurav, Ahmed, Khatija, Aley, Parvinder, Bhikha, Sutika, Bhiman, Jinal N, Bhorat, As’ad E, du Plessis, Jeanine, Esmail, Aliasgar, Groenewald, Marisa, Horne, Elizea, Hwa, Shi-Hsia, Jose, Aylin, Lambe, Teresa, Laubscher, Matt, Malahleha, Mookho, Masenya, Masebole, Masilela, Mduduzi, McKenzie, Shakeel, Molapo, Kgaogelo, Moultrie, Andrew, Oelofse, Suzette, Patel, Faeezah, Pillay, Sureshnee, Rhead, Sarah, Rodel, Hylton, Rossouw, Lindie, Taoushanis, Carol, Tegally, Houriiyah, Thombrayil, Asha, van Eck, Samuel, Wibmer, Constantinos K, Durham, Nicholas M, Kelly, Elizabeth J, Villafana, Tonya L, Gilbert, Sarah, Pollard, Andrew J, de Oliveira, Tulio, Moore, Penny L, Sigal, Alex, Izu, Alane
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae Adolescent Adult Adverse events Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - physiology ChAdOx1 nCoV-19 Clinical trials Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - immunology COVID-19 - prevention & control COVID-19 Serological Testing COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Disease resistance Double-Blind Method Genomes HIV Human immunodeficiency virus Humans Immunogenicity, Vaccine Infections Laboratories Middle Aged Mutation Original Placebos Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Sodium chloride South Africa T-Lymphocytes - physiology Treatment Failure Vaccine efficacy Vaccine Potency Vaccines Viruses Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A double-blind randomized trial in South Africa documented poor efficacy of two doses of the ChAdOx1 nCoV-19 vaccine against the B.1.351 variant of SARS-CoV-2 that emerged in South Africa. Infections occurred in 3.2% of placebo recipients and in 2.5% of vaccine recipients. Thirty-nine of the 42 virus isolates were the B.1.351 variant. None of the cases led to hospitalization or death.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2102214